Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum interleukin-10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Suzuki S, Kamata M, Uchida H, Shimizu T, Okada Y, Ito M, Watanabe A, Mizukawa I, Egawa S, Chijiwa C, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Suzuki S, et al. J Dermatol. 2025 Jan;52(1):122-131. doi: 10.1111/1346-8138.17512. Epub 2024 Oct 20. J Dermatol. 2025. PMID: 39428667
Serum levels of angiogenesis-related factors in patients with psoriasis.
Watanabe A, Kamata M, Shimizu T, Uchida H, Sakurai E, Suzuki S, Nakajima H, Niimura Y, Ito M, Egawa S, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Watanabe A, et al. Among authors: suzuki s. J Dermatol. 2023 Feb;50(2):222-228. doi: 10.1111/1346-8138.16588. Epub 2022 Sep 19. J Dermatol. 2023. PMID: 36120723
Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.
Takeshima R, Kamata M, Suzuki S, Ito M, Watanabe A, Uchida H, Chijiwa C, Okada Y, Azuma S, Nagata M, Egawa S, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Takeshima R, et al. Among authors: suzuki s. J Dermatol. 2024 Sep;51(9):1216-1224. doi: 10.1111/1346-8138.17277. Epub 2024 May 28. J Dermatol. 2024. PMID: 38804254
Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: A case report.
Suzuki S, Kamata M, Ito M, Watanabe A, Uchida H, Chijiwa C, Azuma S, Hayashi K, Sugiura K, Tada Y. Suzuki S, et al. J Dermatol. 2024 Dec;51(12):e416-e418. doi: 10.1111/1346-8138.17337. Epub 2024 Jun 14. J Dermatol. 2024. PMID: 38874489 No abstract available.
Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.
Watanabe A, Kamata M, Okada Y, Suzuki S, Ito M, Uchida H, Chijiwa C, Egawa S, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Watanabe A, et al. Among authors: suzuki s. Exp Dermatol. 2024 Sep;33(9):e15175. doi: 10.1111/exd.15175. Exp Dermatol. 2024. PMID: 39277874
Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.
Nakajima H, Kamata M, Okada Y, Suzuki S, Ito M, Watanabe A, Egawa S, Chijiwa C, Hiura A, Tomura Y, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Nakajima H, et al. Among authors: suzuki s. Exp Dermatol. 2024 Nov;33(11):e70010. doi: 10.1111/exd.70010. Exp Dermatol. 2024. PMID: 39487715
14,409 results
You have reached the last available page of results. Please see the User Guide for more information.